BioVaxys Technology Corp. and Adiverna LLC have entered into a Research Agreement to develop mRNA-based vaccines for rabies, leptospirosis, feline infectious peritonitis (FIV), and other diseases for companion animal veterinary applications. The collaboration combines BioVaxys' DPX™ Immune Educating Platform formulations with novel proprietary mRNA sequences designed and developed by Adiverna using artificial intelligence technology.
Adiverna is pioneering a unique approach in veterinary healthcare by leveraging its proprietary AI technology to design and optimize mRNA sequences for vaccines specifically tailored for companion animals. Currently, no mRNA vaccines are approved for these animals, making Adiverna's focus on this area groundbreaking. By utilizing machine learning algorithms and advanced bioinformatics, Adiverna's AI platform analyzes extensive datasets to identify and predict the most effective mRNA sequences that code for protective broadly cross-neutralizing antigens against diseases such as FIV, rabies, and leptospirosis. Additionally, Adiverna's mRNA platform offers significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses.
"The collaboration between BioVaxys and Adiverna is set to revolutionize routine annual vaccinations for dogs and cats, enhancing their safety and effectiveness while reducing the financial burden on pet owners," says Kirill Kalnin, PhD, Founder and Chief Technology Officer of Adiverna. "Our innovative approach will offer more targeted dosing and improved protection compared to conventional vaccines."
BioVaxys' DPX platform presents antigens to the immune system using a novel non-systemic mechanism of action that does not release active ingredients at the injection site, but rather forces active uptake by immune cells and delivery into lymphatic nodes. This "no release" mechanism allows for active uptake of antigens such as mRNA into immune cells and lymph nodes for sustained activation of the immune system. According to Kenneth Kovan, President and Chief Operating Officer of BioVaxys, "Data from proof-of-concept studies of DPX-mRNA formulations demonstrate that DPX provides enhanced in vitro and in vivo stability of packaged mRNA, attracts a therapeutically unique subset of Antigen Presenting Cells to the injection site for targeted uptake of mRNA by the immune system."
A DPX-formulated mRNA vaccine would offer significant advantages over traditional vaccines by delivering superior, longer-lasting immunity with fewer doses, together with high-level, rapid, and durable neutralizing antibody responses and faster, safer, and more scalable manufacturing. Traditional vaccines for companion animals are generally effective for either 1 year or 3 years, depending on the specific product used and local regulations. A DPX mRNA vaccine would not use viral material and would have fewer impurities, reducing risks associated with injecting foreign, inactivated viruses.
The market potential for these innovations is substantial. The global rabies veterinary vaccines market for inactivated and modified-live virus vector products is valued at US$785 million in 2024, and is projected to reach approximately US$1.1 billion by 2030, growing at a 5.8% CAGR. Annual sales for canine leptospirosis killed vaccine formulations are part of the broader dog vaccine market, which was valued at approximately $2.10 billion in 2025. The FIV vaccine market is part of the broader feline vaccines sector, which is projected to reach USD 3.28 billion by 2034, growing from USD 1.77 billion in 2025, according to Research & Markets, Fortune Business Insights, and Cornell University College of Veterinary Medicine data.
Driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership, the market is dominated by companion animal vaccination in North America, with the Asia/Pacific region experiencing rapid growth due to increasing vaccination campaigns in countries like India and China. "We are very excited to be working with Adiverna to develop what could be the world's first mRNA veterinary vaccine," adds Kovan. "We believe the clinically proven advantages of the DPX platform formulated with Adiverna's AI-designed mRNA sequences will provide for a superior product."
